Back to Results

Telesis Bio Inc (TBIO)

Telesis Bio Inc. is a healthcare company focused on synthetic biology tools and services. The company manufactures and sells instruments, reagents, and related products used mainly by pharmaceutical and academic laboratories around the world. Its product suite includes the BioXp 3250 and BioXp 9600 systems, the BioXp portal for sequence design and workflow support, and a range of kits and benchtop reagents for applications such as DNA assembly, mRNA generation, next-generation sequencing library preparation, and related synthetic biology workflows. Telesis Bio also provides custom DNA synthesis solutions intended for the development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. In addition, the company has a license agreement with Regeneron Pharmaceuticals. Founded in 2011 and headquartered in San Diego, California, it was formerly known as Codex DNA, Inc. before adopting its current name in November 2022.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-TBIO
—
—
—
—
—
—
Weak
—
—
—
0.0%
August 7, 2026
—
—
—
1.801 K
—
—
—
—
—
—
Valuation • Fair Value

Telesis Bio Inc (OTC-TBIO) Fair Value by Valuation Model

Compare the primary fair value estimate for Telesis Bio Inc (OTC-TBIO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

Not available

Data is currently unavailable.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Telesis Bio Inc (OTC-TBIO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Telesis Bio Inc (OTC-TBIO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

Not available

Data is currently unavailable.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Telesis Bio Inc (OTC-TBIO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Telesis Bio Inc (OTC-TBIO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

Not available

Data is currently unavailable.

Beneish M-Score

Not available

Data is currently unavailable.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

Not available

Data is currently unavailable.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Telesis Bio Inc (OTC-TBIO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Telesis Bio Inc (OTC-TBIO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 7, 2026

Days to Earnings

17

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Telesis Bio Inc (OTC-TBIO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Telesis Bio Inc (OTC-TBIO) Stock Forecast & Technical Outlook

Review Telesis Bio Inc (OTC-TBIO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Telesis Bio Inc (OTC-TBIO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Telesis Bio Inc (OTC-TBIO) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Telesis Bio Inc (OTC-TBIO) Stock FAQ

Quick answers about Telesis Bio Inc (OTC-TBIO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

A fair value estimate for Telesis Bio Inc (OTC-TBIO) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

An analyst price target for Telesis Bio Inc (OTC-TBIO) is not currently available in the latest data file.

The current financial health read for Telesis Bio Inc (OTC-TBIO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Telesis Bio Inc (OTC-TBIO) is August 7, 2026.

Based on the current data, dividend yield is 0.0%.

The current market capitalization listed for Telesis Bio Inc is 1.801 K.

The ticker symbol for Telesis Bio Inc is OTC-TBIO, and the stock is listed on OTC Markets.

Telesis Bio Inc (OTC-TBIO) is listed on OTC Markets.

Similar Life Sciences Tools & Services Stocks on OTC Markets View more

Lonza Group AG (LZAGY) Lonza Group AG (LZAGY)
WuXi Biologics (WXIBF) WuXi Biologics (WXIBF)
RADNOSTIX, INC (INIS) RADNOSTIX, INC (INIS)
Malin Corporation plc (MLLNF) Malin Corporation plc (MLLNF)
Bioqual Inc (BIOQ) Bioqual Inc (BIOQ)
Sona Nanotech Inc (SNANF) Sona Nanotech Inc (SNANF)
Pharma-Bio Serv Inc (PBSV) Pharma-Bio Serv Inc (PBSV)
Reflect Scientific Inc (RSCF) Reflect Scientific Inc (RSCF)
Cannabis Bioscience International Holdings Inc (CBIH) Cannabis Bioscience International Holdings Inc (CBIH)
BNB Plus Corp (BNBX) BNB Plus Corp (BNBX)
Pressure Biosciences Inc (PBIO) Pressure Biosciences Inc (PBIO)
EVIO Inc (EVIO) EVIO Inc (EVIO)
MetaStat Inc (MTST) MetaStat Inc (MTST)
BG Medicine Inc (BGMD) BG Medicine Inc (BGMD)
Arrayit Corporation (ARYC) Arrayit Corporation (ARYC)
Response Genetics Inc (RGDXQ) Response Genetics Inc (RGDXQ)